3 ms·
IF it's what you say, then we'll have to set up some form of education to make sure people do value their data correctly, and therefore, a re in a position to n
by wiz21c 8y ago
IF it's what you say, then we'll have to set up some form of education to make sure people do value their data correctly, and therefore, a re in a position to negotiate with that sort of businesses.
Each time a my genome data contributes to one pill to improve the life one person, I want price of the pill P divided by number N of genomes used, divided by 100, so P/(100*N) euro on each pill sold, for my whole life.
- dpflan 8y ago:) I like the idea. The other day I thought of whether it would be possible to create drug company around this premise: select a drug for a chronic illness, when that drug’s patent expires, structure a company around producing that drug for a low enough price point that you can at least break even running a company that employees people and manufactures that drug. Now if prices low enough so that it undercuts competitors and is not a financial burden to patients, you have a monopoly with a real market and one that gets increased based upon the frequency of expression (if genetically based). If you can price the drug just enough to then fund a research and development department, then maybe you have an interesting business. I thought then, could you “donate” the company to the public, almost making it a public utility.